Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs verteporfin PDT in pathologic myopia CNV
jRCT2080221328Phase 3
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in myopic choroidal neovascularisation (mCNV) and myopic maculopathy (MM) (3 arms), sponsored by Novartis.
02
Drugs
ranibizumab
03
Conditions
myopic choroidal neovascularisation (mCNV)myopic maculopathy (MM)
Beyond the preview
Go deeper on jRCT2080221328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221328.